Merck's Strong Keytruda Sales Drive Earnings and Outlook
TL;DR Summary
Merck's Q3 earnings surpassed estimates driven by strong Keytruda sales, reaching over $8 billion, while adjusting its full-year profit outlook downward due to lower tariff costs and challenges in China sales of Gardasil. The company plans to cut costs and offset revenue losses from upcoming patent expirations, with revenue guidance narrowed for 2023.
- Merck tops estimates on Keytruda strength and narrows profit outlook, as it lowers estimated tariff hit CNBC
- Merck Beat Quarterly Sales Expectations Amid Pivot to New Drugs Bloomberg.com
- Merck Profit Rises on Strong Keytruda Demand The Wall Street Journal
- Merck’s record cancer drug sales power earnings growth Financial Times
- Merck (MRK) Reports Earnings Tomorrow: What To Expect Yahoo Finance
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
3 min
vs 4 min read
Condensed
93%
721 → 53 words
Want the full story? Read the original article
Read on CNBC